Welcome to our dedicated page for American Well news (Ticker: AMWL), a resource for investors and traders seeking the latest updates and insights on American Well stock.
American Well Corporation, known as Amwell (NYSE: AMWL), regularly issues news and updates about its role in digital care and technology-enabled healthcare. Company announcements highlight its SaaS-based care platform, relationships with payers, health systems and government organizations, and its ongoing work to support digital and hybrid care models.
On this news page, readers can follow Amwell’s earnings announcements and quarterly operating updates, which are often accompanied by investor conference calls and webcasts. The company frequently reports the timing of its financial results, provides access details for live audio webcasts and notes the availability of replay links through its investor resources.
Amwell’s news flow also covers commercial partnerships and contracts. For example, the company has reported on its role in the U.S. Defense Health Agency’s Digital First Program for the Military Health System, where its technology-enabled care platform powers virtual visits integrated with the MHS GENESIS electronic health record. News items describe how the platform supports military care teams, service members and their families across the global Department of Defense enterprise.
Investors and observers can also see updates on Amwell’s agreements with Elevance Health related to the LiveHealth Online white‑label digital care platform, as well as disclosures about equity inducement grants to new employees under its inducement plan. Together, these items provide insight into Amwell’s operational priorities, customer relationships and use of technology to support digital care programs.
For anyone tracking AMWL, this news feed brings together company-issued releases on financial results, major contracts, investor conference participation and corporate actions, offering a centralized view of Amwell’s public communications about its technology-enabled care business.
Amwell (NYSE: AMWL) announced equity compensation grants to new employees under its Inducement Plan. The company granted 254,227 restricted stock units (RSUs) to Mark Hirschhorn, its new CFO, with 25% vesting immediately and the remaining 75% vesting quarterly over three years. Hirschhorn is also eligible for an additional $5 million grant subject to EBITDA targets and company valuation goals, vesting annually over four years. Additionally, 5,084 RSUs were granted to two other new employees, with 25% vesting after one year and the remaining 75% vesting quarterly over three years.
Amwell (NYSE: AMWL), a leading provider of healthcare software as a service, reported its third quarter 2024 financial results for the period ending Sept. 30, 2024. The company will host a conference call today at 5 p.m. ET to discuss these results. The call can be accessed via a live audio webcast on Amwell's investor relations website or by dialing 1-888-510-2008 for U.S. participants and 1-646-960-0306 for international participants, using conference ID number 7830032. A replay will be available shortly afterward on the same website.
Amwell (NYSE: AMWL), a digital care leader, has announced its participation in four upcoming investor conferences in November and December 2024. Chairman and CEO Ido Schoenberg and CFO Mark Hirschhorn will engage in fireside chats and one-on-one meetings at these events.
The schedule includes the UBS Global Healthcare Conference in Palos Verdes on Nov. 12, the Needham Consumer Tech Conference on Nov. 20, the BTIG Virtual Health Forum on Nov. 25, and the Piper Sandler Healthcare Conference in New York on Dec. 4. Audio webcasts of the fireside chats will be accessible at investors.amwell.com.
Amwell (NYSE: AMWL), a digital care leader, has announced Mark Hirschhorn as its new Chief Financial Officer (CFO), effective October 21. Hirschhorn, with over 30 years of experience in healthcare technology, will oversee Amwell's financial operations, optimization, and capital allocation activities. He succeeds Robert Shepardson, who has held the position since 2021.
Hirschhorn's appointment marks a shift for Amwell as it moves from intense R&D investment to an operational focus on efficiency, cash flow optimization, and profitable growth. His experience includes roles as CEO at TapestryHealth and CFO/COO positions at Teladoc Health and Talkspace. Amwell's CEO, Dr. Ido Schoenberg, expressed confidence in Hirschhorn's ability to lead the company for the benefit of all stakeholders.
Amwell® (NYSE: AMWL), a digital care leader, has announced it will release its third quarter 2024 operating results on Wednesday, October 30. Following the earnings alert distribution, the company's management team will host a live conference call and webcast at 5 p.m. ET to discuss the results and provide a business update. Investors can access the full earnings report and live audio webcast through the Investors section of Amwell's website. A replay of the webcast will be available at investors.amwell.com for approximately 90 days after the call.
Amwell (NYSE: AMWL) has announced a partnership with Hello Heart, integrating the digital preventive heart health solution into its clinical programs portfolio on the Amwell Converge™ platform. This collaboration allows Amwell health plan clients to offer their employer accounts Hello Heart's cardiovascular solution to eligible members with high blood pressure, high cholesterol, or other cardiovascular disease risk factors.
Members can access Hello Heart's solution through their existing Amwell-powered offering, alongside virtual primary care, urgent care, behavioral health, and other clinical programs. The program provides users with a connected blood pressure monitor and an app offering personalized daily coaching and metric tracking. This integration aims to address the clinical and financial burden of heart disease, which costs health plans an average of $12,500 per member per year.
Amwell (NYSE: AMWL), a leader in hybrid care enablement, has announced its participation in several investor conferences this September. Key events include:
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 4, featuring a fireside chat at 1:50 p.m. ET
• Wells Fargo Healthcare Conference in Boston on September 5 (one-on-one meetings only)
• Baird Healthcare Conference in New York City on September 10, with one-on-one investor meetings
• TD Cowen 9th Annual FutureHealth Conference in New York City on September 10, including a panel discussion at 2:20 p.m. ET
Ido Schoenberg, M.D., Amwell's chairman and CEO, and Robert Shepardson, CFO, will represent the company. Audio webcasts of the Morgan Stanley fireside chat and TD Cowen panel will be available at investors.amwell.com.
Amwell (NYSE: AMWL), a small-cap growth healthcare company specializing in healthcare software as a service, has released its financial results for the second quarter of 2024, ending June 30. The company has made the detailed earnings report available on its investor relations website. Amwell will host a conference call on July 31, 2024, at 5 p.m. ET to discuss the financial results. Interested parties can access the call via a live audio webcast or by dialing in, with separate numbers provided for U.S. and international participants. A replay of the call will be available on the company's website after the event concludes.
Amwell® (NYSE: AMWL), a leader in hybrid care enablement, has announced it will report its second quarter 2024 operating results on Wednesday, July 31. The company will host a live conference call and webcast at 5 p.m. ET on the same day to review the results and provide a general business update. Investors can access the audio webcast through the Investors section of Amwell's website or join the conference call using the provided phone numbers. A replay of the webcast will be available at investors.amwell.com for approximately 90 days after the event.
Amwell (NYSE: AMWL) announced a 1-for-20 reverse stock split of its Class A, B, and C common stock, effective on July 10, 2024, at 5:00 p.m. EDT. Trading on a split-adjusted basis will commence on July 11, 2024, under the same symbol, 'AMWL'.
The primary objective is to comply with the NYSE's $1.00 minimum average closing price requirement. This action will reduce the number of issued and outstanding shares across all classes by a factor of 20, without affecting the company's market capitalization.
Shareholders approved the reverse split at Amwell's annual meeting on June 18, 2024, choosing a split ratio between 1-for-10 and 1-for-20, with the final decision made by the Board on June 27, 2024. No fractional shares will be issued; instead, cash payments will be made for fractional entitlements.
The new CUSIP number for Class A shares will be 03044L 204 post-split. All outstanding options, warrants, and equity incentive plans will be adjusted accordingly. The par value remains unchanged at $0.01 per share.
FAQ
What is the current stock price of American Well (AMWL)?
What is the market cap of American Well (AMWL)?
